For research use only. Not for therapeutic Use.
Ondansetron (GR 38032) hydrochloride dehydrate is an orally active, highly selective and competitive 5-HT3 receptor antagonist (crosses the blood-brain barrier). Ondansetron hydrochloride dehydrate can be used in studies of preventing nausea and vomiting associated with cancer chemotherapy, radiation therapy and surgery[1][2].
Ondansetron hydrochloride dehydrate (2 mg/kg; i.p.; single) blocks radiation sickness when combines with Dexamethasone (2 mg/kg) and CP-99,994 (15 mg/kg), in radiation-induced pica model[1].
| Catalog Number | I000217 |
| CAS Number | 103639-04-9 |
| Synonyms | 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one;dihydrate;hydrochloride |
| Molecular Formula | C18H24ClN3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C18H19N3O.ClH.2H2O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2;;;/h3-6,9-10,13H,7-8,11H2,1-2H3;1H;2*1H2 |
| InChIKey | VRSLTNZJOUZKLX-UHFFFAOYSA-N |
| SMILES | CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C.O.O.Cl |
| Reference | [1]. Yamamoto K, et al. Ondansetron, dexamethasone and an NK1 antagonist block radiation sickness in mice. Pharmacol Biochem Behav. 2005 Sep;82(1):24-9. [2]. Wilde MI, et al. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs. 1996 Nov;52(5):773-94. |
